Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Drug Class (Second- generation Antipsychotics, Third-Generation Antipsychotics), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Schizophrenia Drugs Market Growth & Trends
The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.
Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.
The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies’ ITI-007 and Alkermes’ ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.
Schizophrenia Drugs Market Report Highlights
Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.
Sumitomo Pharma Co., Ltd.
Eli Lilly and Company
Alkermes
VANDA PHARMACEUTICALS
AstraZeneca plc
AbbVie Inc.
Pfizer Inc.
H. Lundbeck A/S
Schizophrenia Drugs Market Growth & Trends
The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.
Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.
The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies’ ITI-007 and Alkermes’ ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.
Schizophrenia Drugs Market Report Highlights
- The second-generation-antipsychotics held the largest market revenue share of 73.05% in 2024. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics.
- The injectable antipsychotics treatment segment held the largest market revenue share in 2024. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications.
- The hospital pharmacies segment held the largest market revenue share in 2024. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition.
- North America schizophrenia drugs market held the largest market revenue share of 38.65% in 2024. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders.
Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.
Sumitomo Pharma Co., Ltd.
Eli Lilly and Company
Alkermes
VANDA PHARMACEUTICALS
AstraZeneca plc
AbbVie Inc.
Pfizer Inc.
H. Lundbeck A/S
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Class
1.2.2. Treatment
1.2.3. Treatment
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class and Route of Administration Outlook
2.2.2. Distribution Channel Outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. SCHIZOPHRENIA DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Schizophrenia Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
CHAPTER 4. SCHIZOPHRENIA DRUGS MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard
4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis
4.3. Global Schizophrenia Drugs Market by Class, Revenue
4.4. Second-Generation Antipsychotics
4.4.1. Second-Generation Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1. Risperdal (Risperidone)
4.4.1.1.1. Risperdal (Risperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Invega (Paliperidone)
4.4.1.2.1. Invega (Paliperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Zyprexa (Olanzapine)
4.4.1.3.1. Zyprexa (Olanzapine) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Geodon (Ziprasidone)
4.4.1.4.1. Geodon (Ziprasidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Seroquel (Quetiapine)
4.4.1.5.1. Seroquel (Quetiapine) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.6. Latuda (Lurasidone)
4.4.1.6.1. Latuda (Lurasidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.7. Aristada (Aripiprazole Lauroxil)
4.4.1.7.1. Aristada (Aripiprazole Lauroxil) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.8. Fanapt (Iloperidone)
4.4.1.8.1. Fanapt (Iloperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.9. Vraylar (Cariprazine)
4.4.1.9.1. Vraylar (Cariprazine) market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Third-Generation Antipsychotics
4.5.1. Schizophrenia Drugs market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. SCHIZOPHRENIA DRUGS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard
5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis
5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue
5.4. Oral Antipsychotics
5.4.1. Oral Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Injectable Antipsychotics
5.5.1. Injectable Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. SCHIZOPHRENIA DRUGS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard
6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis
6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Others
6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. SCHIZOPHRENIA DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS, DISTRIBUTION CHANNEL, AND ROUTE OF ADMINISTRATION
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Johnson & Johnson Services, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Class benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Class benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Sumitomo Pharma Co., Ltd.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Class benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Eli Lilly and Company
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Class benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Alkermes
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Class benchmarking
8.3.8.4. Strategic initiatives
8.3.9. VANDA PHARMACEUTICALS
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Class benchmarking
8.3.9.4. Strategic initiatives
8.3.10. AstraZeneca
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Class benchmarking
8.3.10.4. Strategic initiatives
8.3.11. AbbVie Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Class benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Pfizer Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Class benchmarking
8.3.12.4. Strategic initiatives
8.3.13. H. Lundbeck A/S
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Class benchmarking
8.3.13.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Class
1.2.2. Treatment
1.2.3. Treatment
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class and Route of Administration Outlook
2.2.2. Distribution Channel Outlook
2.2.3. Regional outlook
2.3. Competitive Insights
CHAPTER 3. SCHIZOPHRENIA DRUGS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Schizophrenia Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pricing Analysis
3.3.4. Pipeline Analysis
3.3.4.1. Phase 1
3.3.4.2. Phase 2
3.3.4.3. Phase 2
CHAPTER 4. SCHIZOPHRENIA DRUGS MARKET: DRUG CLASS ESTIMATES & TREND ANALYSIS
4.1. Global Schizophrenia Drugs Market: Drug Class Dashboard
4.2. Global Schizophrenia Drugs Market: Drug Class Movement Analysis
4.3. Global Schizophrenia Drugs Market by Class, Revenue
4.4. Second-Generation Antipsychotics
4.4.1. Second-Generation Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.1. Risperdal (Risperidone)
4.4.1.1.1. Risperdal (Risperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Invega (Paliperidone)
4.4.1.2.1. Invega (Paliperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Zyprexa (Olanzapine)
4.4.1.3.1. Zyprexa (Olanzapine) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Geodon (Ziprasidone)
4.4.1.4.1. Geodon (Ziprasidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Seroquel (Quetiapine)
4.4.1.5.1. Seroquel (Quetiapine) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.6. Latuda (Lurasidone)
4.4.1.6.1. Latuda (Lurasidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.7. Aristada (Aripiprazole Lauroxil)
4.4.1.7.1. Aristada (Aripiprazole Lauroxil) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.8. Fanapt (Iloperidone)
4.4.1.8.1. Fanapt (Iloperidone) market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.9. Vraylar (Cariprazine)
4.4.1.9.1. Vraylar (Cariprazine) market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Third-Generation Antipsychotics
4.5.1. Schizophrenia Drugs market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. SCHIZOPHRENIA DRUGS MARKET: ROUTE OF ADMINISTRATION ESTIMATES & TREND ANALYSIS
5.1. Global Schizophrenia Drugs Market: Route of Administration Dashboard
5.2. Global Schizophrenia Drugs Market: Route of Administration Movement Analysis
5.3. Global Schizophrenia Drugs Market by Route of Administration , Revenue
5.4. Oral Antipsychotics
5.4.1. Oral Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Injectable Antipsychotics
5.5.1. Injectable Antipsychotics market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. SCHIZOPHRENIA DRUGS MARKET: DISTRIBUTION CHANNEL ESTIMATES & TREND ANALYSIS
6.1. Global Schizophrenia Drugs Market: Distribution Channel Dashboard
6.2. Global Schizophrenia Drugs Market: Distribution Channel Movement Analysis
6.3. Global Schizophrenia Drugs Market by Distribution Channel, Revenue
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Others
6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. SCHIZOPHRENIA DRUGS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY DRUG CLASS, DISTRIBUTION CHANNEL, AND ROUTE OF ADMINISTRATION
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. Johnson & Johnson Services, Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Class benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Bristol-Myers Squibb Company/ Otsuka Holdings Co., Ltd.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Class benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Sumitomo Pharma Co., Ltd.
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Class benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Eli Lilly and Company
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Class benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Alkermes
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Class benchmarking
8.3.8.4. Strategic initiatives
8.3.9. VANDA PHARMACEUTICALS
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Class benchmarking
8.3.9.4. Strategic initiatives
8.3.10. AstraZeneca
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Class benchmarking
8.3.10.4. Strategic initiatives
8.3.11. AbbVie Inc.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Class benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Pfizer Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Class benchmarking
8.3.12.4. Strategic initiatives
8.3.13. H. Lundbeck A/S
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Class benchmarking
8.3.13.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviation
Table 2 North America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 3 North America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 4 North America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 5 U.S. Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 6 U.S. Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 7 U.S. Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Canada Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 9 Canada Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 10 Canada Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 Mexico Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 12 Mexico Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 13 Mexico Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Europe Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 15 Europe Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 16 Europe Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 18 Germany Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 19 Germany Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 UK Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 21 UK Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 22 UK Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 France Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 24 France Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 25 France Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Italy Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 27 Italy Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 28 Italy Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 29 Spain Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 30 Spain Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 31 Spain Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Asia Pacific Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 33 Asia Pacific Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 China Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 36 China Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 37 China Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Japan Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 39 Japan Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 40 Japan Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 India Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 42 India Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 43 India Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 South Korea Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 45 South Korea Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 46 South Korea Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Latin America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 48 Latin America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 49 Latin America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 50 Brazil Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 51 Brazil Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 52 Brazil Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 53 MEA Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 54 MEA Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 55 MEA Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 56 South Africa Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 57 South Africa Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 58 South Africa Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 62 UAE Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 63 UAE Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 64 UAE Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 65 Kuwait Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 66 Kuwait Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 67 Kuwait Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 1 List of abbreviation
Table 2 North America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 3 North America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 4 North America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 5 U.S. Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 6 U.S. Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 7 U.S. Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 8 Canada Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 9 Canada Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 10 Canada Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 11 Mexico Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 12 Mexico Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 13 Mexico Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 14 Europe Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 15 Europe Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 16 Europe Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 17 Germany Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 18 Germany Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 19 Germany Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 20 UK Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 21 UK Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 22 UK Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 23 France Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 24 France Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 25 France Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 26 Italy Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 27 Italy Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 28 Italy Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 29 Spain Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 30 Spain Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 31 Spain Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 32 Asia Pacific Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 33 Asia Pacific Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 34 Asia Pacific Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 35 China Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 36 China Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 37 China Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 38 Japan Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 39 Japan Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 40 Japan Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 41 India Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 42 India Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 43 India Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 44 South Korea Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 45 South Korea Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 46 South Korea Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 47 Latin America Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 48 Latin America Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 49 Latin America Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 50 Brazil Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 51 Brazil Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 52 Brazil Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 53 MEA Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 54 MEA Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 55 MEA Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 56 South Africa Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 57 South Africa Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 58 South Africa Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 61 Saudi Arabia Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 62 UAE Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 63 UAE Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 64 UAE Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
Table 65 Kuwait Schizophrenia Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
Table 66 Kuwait Schizophrenia Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
Table 67 Kuwait Schizophrenia Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Schizophrenia Drugs market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Drug Class and Route of Administration segment snapshot
Fig. 10 Route of Administration segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Pharmaceutical market, (USD Billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Schizophrenia Drugs market: Drug Class Outlook and key takeaways
Fig. 17 Schizophrenia Drugs market: Drug Class movement analysis
Fig. 18 Second-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Risperdal (Risperidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Invega (Paliperidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Zyprexa (Olanzapine) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Geodon (Ziprasidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Seroquel (Quetiapine) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Latuda (Lurasidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Aristada (Aripiprazole Lauroxil) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Fanapt (Iloperidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Saphris (Asenapine) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Vraylar (Cariprazine) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Third-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Abilify (Aripiprazole) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Schizophrenia Drugs market: Route of Administration Outlook and key takeaways
Fig. 33 Schizophrenia Drugs market: Route of Administration movement analysis
Fig. 34 Oral Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Injectable Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Schizophrenia Drugs market: Distribution Channel Outlook and key takeaways
Fig. 37 Schizophrenia Drugs market: Distribution Channel movement analysis
Fig. 38 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Schizophrenia Drugs market revenue, by region, 2024 & 2030, (USD Million)
Fig. 43 Regional marketplace: Key takeaways
Fig. 44 North America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Target disease prevalence
Fig. 47 U.S. schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence
Fig. 50 Canada schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Mexico schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 Target disease prevalence
Fig. 54 Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Target disease prevalence
Fig. 57 UK schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Key country dynamics
Fig. 59 Target disease prevalence
Fig. 60 Germany schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Target disease prevalence
Fig. 63 France schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Target disease prevalence
Fig. 66 Spain schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Key country dynamics
Fig. 68 Target disease prevalence
Fig. 69 Italy schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Target disease prevalence
Fig. 72 Denmark schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 Target disease prevalence
Fig. 75 Sweden schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Target disease prevalence
Fig. 78 Norway schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Rest of Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 Target disease prevalence
Fig. 83 Japan schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Target disease prevalence
Fig. 86 China schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 Target disease prevalence
Fig. 89 India schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 Target disease prevalence
Fig. 92 Australia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Key country dynamics
Fig. 94 Thailand schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 South Korea schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Rest of Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 Key country dynamics
Fig. 100 Target disease prevalence
Fig. 101 Brazil schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 Key country dynamics
Fig. 103 Target disease prevalence
Fig. 104 Argentina schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 105 Rest of Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 107 Key country dynamics
Fig. 108 Target disease prevalence
Fig. 109 South Africa schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Key country dynamics
Fig. 111 Target disease prevalence
Fig. 112 Saudi Arabia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 113 Key country dynamics
Fig. 114 Target disease prevalence
Fig. 115 UAE schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 116 Key country dynamics
Fig. 117 Target disease prevalence
Fig. 118 Kuwait schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 119 Rest of MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Schizophrenia Drugs market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Drug Class and Route of Administration segment snapshot
Fig. 10 Route of Administration segment snapshot
Fig. 11 Competitive landscape snapshot
Fig. 12 Pharmaceutical market, (USD Billion)
Fig. 13 Market dynamics
Fig. 14 Porter’s five forces analysis
Fig. 15 PESTLE analysis
Fig. 16 Schizophrenia Drugs market: Drug Class Outlook and key takeaways
Fig. 17 Schizophrenia Drugs market: Drug Class movement analysis
Fig. 18 Second-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Risperdal (Risperidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Invega (Paliperidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Zyprexa (Olanzapine) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Geodon (Ziprasidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Seroquel (Quetiapine) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Latuda (Lurasidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Aristada (Aripiprazole Lauroxil) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Fanapt (Iloperidone) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Saphris (Asenapine) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Vraylar (Cariprazine) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Third-Generation Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 Abilify (Aripiprazole) market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Schizophrenia Drugs market: Route of Administration Outlook and key takeaways
Fig. 33 Schizophrenia Drugs market: Route of Administration movement analysis
Fig. 34 Oral Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Injectable Antipsychotics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Schizophrenia Drugs market: Distribution Channel Outlook and key takeaways
Fig. 37 Schizophrenia Drugs market: Distribution Channel movement analysis
Fig. 38 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Online Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Schizophrenia Drugs market revenue, by region, 2024 & 2030, (USD Million)
Fig. 43 Regional marketplace: Key takeaways
Fig. 44 North America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Key country dynamics
Fig. 46 Target disease prevalence
Fig. 47 U.S. schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Key country dynamics
Fig. 49 Target disease prevalence
Fig. 50 Canada schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Mexico schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Key country dynamics
Fig. 53 Target disease prevalence
Fig. 54 Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Key country dynamics
Fig. 56 Target disease prevalence
Fig. 57 UK schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Key country dynamics
Fig. 59 Target disease prevalence
Fig. 60 Germany schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 Key country dynamics
Fig. 62 Target disease prevalence
Fig. 63 France schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Key country dynamics
Fig. 65 Target disease prevalence
Fig. 66 Spain schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Key country dynamics
Fig. 68 Target disease prevalence
Fig. 69 Italy schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Key country dynamics
Fig. 71 Target disease prevalence
Fig. 72 Denmark schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 Target disease prevalence
Fig. 75 Sweden schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 76 Key country dynamics
Fig. 77 Target disease prevalence
Fig. 78 Norway schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Rest of Europe schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 80 Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Key country dynamics
Fig. 82 Target disease prevalence
Fig. 83 Japan schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 Target disease prevalence
Fig. 86 China schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 87 Key country dynamics
Fig. 88 Target disease prevalence
Fig. 89 India schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 Target disease prevalence
Fig. 92 Australia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 Key country dynamics
Fig. 94 Thailand schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Key country dynamics
Fig. 96 South Korea schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Rest of Asia Pacific schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 98 Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 99 Key country dynamics
Fig. 100 Target disease prevalence
Fig. 101 Brazil schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 102 Key country dynamics
Fig. 103 Target disease prevalence
Fig. 104 Argentina schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 105 Rest of Latin America schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 106 MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 107 Key country dynamics
Fig. 108 Target disease prevalence
Fig. 109 South Africa schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 110 Key country dynamics
Fig. 111 Target disease prevalence
Fig. 112 Saudi Arabia schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 113 Key country dynamics
Fig. 114 Target disease prevalence
Fig. 115 UAE schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 116 Key country dynamics
Fig. 117 Target disease prevalence
Fig. 118 Kuwait schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 119 Rest of MEA schizophrenia drugs market estimates and forecasts, 2018 - 2030 (USD Million)
